Completed PHASE1 INTERVENTIONAL 1-arm NCT02216617

Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (TAPIS)

A Phase I Study Evaluating the Combination Afatinib With Docetaxel and Cisplatin (TPA) in Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Upper Aerodigestive Tract

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Conditions HNSCC

Interventions Taxotere, Cisplatin, Afatinib

Updated 6 times since 2017 Last updated: Oct 25, 2017 Started: Aug 6, 2014 Primary completion: Jul 31, 2015 Completion: Sep 15, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HNSCC, this trial is completed. The trial is conducted by Groupe Oncologie Radiotherapie Tete et Cou and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Nov 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — Nov 2017 [monthly]

Unknown Status PHASE1

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Groupe Oncologie Radiotherapie Tete et Cou

Data source: Groupe Oncologie Radiotherapie Tete et Cou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France